NovoCure Limited (NASDAQ:NVCR) Receives $32.67 Consensus Target Price from Analysts
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price […]
NovoCure Limited (NASDAQ:NVCR – Get Free Report) has been given an average recommendation of “Moderate Buy” by the six research firms that are presently covering the company, MarketBeat.com reports. Two research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month target price […]
